Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma

Ed Miseta

Ed Miseta

For more than a decade, Ed Miseta served as the Chief Editor of Clinical Leader. His tenure sadly ended in July 2023 when he passed away after a two-year battle with multiple myeloma. During his time as Chief Editor, Ed interviewed hundreds of executives from sponsor companies, patients, and technology and service providers. He regularly reported on best practices and advancements in clinical trials, detailing how both small and large sponsor companies navigate the changing landscape. In addition to his writing, Ed hosted numerous Clinical Leader Live! digital events that allowed his audience to listen to and interact with experts throughout clinical trials on a host of important issues. Beyond his duties for Clinical Leader, Ed frequently moderated and spoke at many conferences and events related to clinical trials.

Ed studied Business Economics at Penn State University and earned a Master’s degree in Business Administration. He spent 10 years in banking and investments and taught economics at Penn State for 8 years before joining Clinical Leader.


Portage Bio_450x300
How Portage Biotech Created A Lean, New Drug Development Model
Dr. Ian Walters noticed that Big Pharma companies often would lament that small biotechs did not develop drugs the same way as their larger counterparts. He set out to change that.  Continue Reading..
South Rampart_450x300
A New Funding Model For A New Approach To Pain
The business model CEO Dr. Hernan Bazan and his colleagues put in place at South Rampart Pharma was not typical for a small biotech firm.  Continue Reading..
Clinical Trials Outlook_FEATURE_450x300
How Are DCTs Impacting Your Clinical Sites?
Where do your sites stand on DCTs? For this article, we spoke with three site experts who discussed the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.  Continue Reading..
UCB CRO Oversight_Ian_450x300
What Is A Risk-Based Approach To CRO Oversight?
Ian Wyglendowski, the head of strategic clinical partnering at UCB, recommends taking a risk-based approach to CRO oversight, and gives specifics that you can implement.  Continue Reading..
Teamwork puzzle problem solve GettyImages-1313291958
How To Become A Sponsor Of Choice For Your CRO Partners
Becoming a true sponsor of choice involves much more than simply saying the words. Drug discovery is a tough business and there are many parts that must seamlessly interact to get a product to regulatory approval.  Continue Reading..
CRO Supp Feature_450x300
Takeda's Mission To Improve Communication With Patients, Sites, And CROs
Being a better partner for your patients, sites, and CROs begins with effective communication. When Karen Correa joined Takeda as VP, head of global clinical operations, she made improved communications her top priority.  Continue Reading..
01_FromThe CRO 0517_450by300
Why I'm Thankful For Sponsors And CROs
There are many patients out there who depend on those efforts and the amazing medicines that result from them. I am now one of them.  Continue Reading..
ed miseta headshot
Do Patients Really Want Hybrid Clinical Trials?
“Decentralized and hybrid trials offer convenience, but that convenience must be balanced with individual preferences. We are entering an age of more personalized and customized participant experiences, and we have to figure out how to manage that,” says Ken Getz of CISCRP.  Continue Reading..
Clinical trials headshots_450x300
Is Janssen's Pathway Approach The Future Of Drug Development
Two Janssen execs talk about the future of what they call a pathway approach to developing new medicines, which attempts to match the biology of a pathway to unmet medical need for patients, across a broad range of immune-mediated, inflammatory disease.  Continue Reading..
From Fusion Energy To Med Device … To Drug Developer?
TAE Life Sciences wanted to create a combination product that brought together its neutron beam with a drug that delivers boron to cancer cells. But, the company didn’t want to be in a position where it relied on another company for the drug needed.  Continue Reading..